News stories about Cytosorbents (NASDAQ:CTSO) have trended somewhat positive on Thursday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytosorbents earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 47.4032894511475 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- Cytosorbents Co. (CTSO) CFO Kathleen P. Bloch Sells 10,000 Shares (americanbankingnews.com)
- $2.65 EPS Expected for Laboratory of America Holdings (LH); Cytosorbents Has 2.89 Sentiment (mtastar.com)
- Cytosorbents Co. (CTSO) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Cytosorbents (CTSO) Reaches $7.20 After 3.00% Down Move; Esterline Technologies (ESL) Shorts Decreased By 3.57% (mtastar.com)
- Cytosorbents Corporation (CTSO) Attaining Market Attention on Technical Facts (investingbizz.com)
CTSO has been the subject of a number of recent analyst reports. Maxim Group set a $12.00 price objective on Cytosorbents and gave the stock a “buy” rating in a research note on Monday, December 11th. ValuEngine downgraded Cytosorbents from a “hold” rating to a “sell” rating in a research report on Friday, December 15th. B. Riley set a $11.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Friday, December 22nd. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Cytosorbents in a research report on Tuesday, January 9th. Finally, Cowen set a $9.00 target price on Cytosorbents and gave the stock a “buy” rating in a research report on Thursday, March 8th. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $11.05.
Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Thursday, March 8th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. The company had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. research analysts forecast that Cytosorbents will post -0.47 earnings per share for the current year.
In other Cytosorbents news, CFO Kathleen P. Bloch sold 11,176 shares of the company’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $8.25, for a total transaction of $92,202.00. Following the sale, the chief financial officer now directly owns 261,246 shares in the company, valued at $2,155,279.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Kathleen P. Bloch sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $8.00, for a total value of $80,000.00. Following the sale, the chief financial officer now owns 268,870 shares in the company, valued at $2,150,960. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 67,080 shares of company stock worth $513,930. Company insiders own 5.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/2018/04/06/cytosorbents-ctso-getting-somewhat-favorable-news-coverage-report-shows/2029292.html.
Cytosorbents Company Profile
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.